Literature DB >> 19513648

A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery.

Jean Labrecque1, Rebecca S Y Wong, Simon P Fricker.   

Abstract

Chemokines are a family of chemoattractant cytokines involved in leukocyte trafficking, activation, development, and hematopoeisis. Chemokines and their receptors have been implicated in several disease processes, particularly inflammatory and autoimmune disorders and cancer, and are therefore attractive targets for drug development. Chemokine receptors are members of the seven-transmembrane, G protein-coupled receptor (GPCR) family. As such they can be studied using GPCR assays such as ligand binding, G protein activation, and downstream signaling processes such as intracellular calcium flux. In this respect assessing GPCR activation by GTP binding is an important tool to study the early stage of signal transduction. Previously this has been done using the radiolabeled non-hydrolyzable GTP analogue [(35)S]GTPgammaS. In order to avoid the problems involved in working with radioactivity, a new non-radioactive version of the assay has been developed using a europium-labeled GTP analogue in which europium-GTP binding can be assayed using time-resolved fluorescence. We have adapted this assay for chemokine receptors. In this chapter, using the chemokine receptor CXCR4 as an example, we describe the steps for assay optimization. In addition we describe adaptation of this assay for the high-throughput screening of chemokine antagonists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513648     DOI: 10.1007/978-1-60327-317-6_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  A homogeneous method to measure nucleotide exchange by α-subunits of heterotrimeric G-proteins using fluorescence polarization.

Authors:  Robin E Muller; Klara R Klein; Stephanie Q Hutsell; David P Siderovski; Adam J Kimple
Journal:  Assay Drug Dev Technol       Date:  2010-07-27       Impact factor: 1.738

3.  Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists.

Authors:  Nicola J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-13       Impact factor: 5.555

Review 4.  Tools for GPCR drug discovery.

Authors:  Ru Zhang; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

Review 5.  Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives.

Authors:  Lin Hong; Larry A Sklar
Journal:  Front Mol Neurosci       Date:  2014-06-05       Impact factor: 5.639

6.  C-terminal engineering of CXCL12 and CCL5 chemokines: functional characterization by electrophysiological recordings.

Authors:  Antoine Picciocchi; Lina Siaučiūnaiteė-Gaubard; Isabelle Petit-Hartlein; Rabia Sadir; Jean Revilloud; Lydia Caro; Michel Vivaudou; Franck Fieschi; Christophe Moreau; Corinne Vivès
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

7.  Development of time-resolved fluorescent based [EU]-GTP binding assay for selection of human Histamine 3 receptor antagonists/inverse agonist: a potential target for Alzheimer's treatment.

Authors:  Jitendra K Singh; Reema C Maniyar; Vikas S Shirsath
Journal:  Ann Neurosci       Date:  2012-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.